New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How do you approach the risk/benefit discussion for IV iron in a patient with concomitant severe iron deficiency and elevated hematocrit due to supra-physiologic testosterone supplementation?

1 Answers

Mednet MemberInvited Expert
Hematology · Georgetown University School of Medicine

I only administer iron if symptomatic (pagophagia, RLS, etc). I have not seen iron deficiency with testosterone prior to phlebotomy. When it is required, I literally walk both sides of the aisle. If a non-phlebotomized patient presented with ID, I would work it up like any other. If I have to treat,...

In your practice, would you consider the all-oral option of decitabine-cedazuridine + venetoclax for an elderly, unfit AML patient, based on the ASCERTAIN-V trial results?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

I see the combination of oral decitabine-cedazuridine (ASTX727) + venetoclax as largely being an appropriate option for any patient with newly diagnosed AML that would be otherwise considered for azacitidine + venetoclax. The inclusion criteria for ASCERTAIN-V (Roboz et al., PMID 42235013) and VIALE...

Do you use anti-microbial prophylaxis when you prescribe ibrutinib?

3
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Columbia University Medical Center

Traditionally, H.Zoster and PJP prophylaxis was more routinely administered in CLL patients receiving chemoimmunotherapy as these regimens were typically more myelosuppressive as well as immunosuppressive. In the era of the novel BCR receptor agents with the approval of ibrutinib and idelalisib and ...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How do you manage persistent cytopenias in patients with AML who achieve a complete remission with incomplete count recovery after venetoclax and HMA?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · UNC Lineberger Comprehensive Cancer Center

This is an important question. How to manage cytopenias on HMA + venetoclax-based regimens is one of the biggest conundrums in the management of AML. The clinical trials to date have not uniformly answered this question based on level 1 evidence. These recommendations are mainly based on anecdotal d...

Do you routinely stop ESA when starting myelofibrosis patients on JAK inhibitor therapy?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

The management of myelofibrosis with anemia is becoming increasingly nuanced, given the several JAK inhibitors available to us and the potential for add-on therapies! An excellent resource to consider regarding decision-making is Jain et al., PMID 39808793. Regarding this specific question at hand, ...

Do you use lenalidomide for patients with MDS with 5q- without other cytogenetic abnormalities but with one or more mutations on NGS?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

For patients who meet the definition of del(5q) syndrome, I typically utilize lenalidomide regardless of the molecular features of the disease. The original publication (List et al., PMID 15703420), the phase III MDS-004 study (Fenaux et al., PMID 21753188), and the phase III SintraREV study (Díez-C...

In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?

6
5 Answers

Mednet Member
Rheumatology · Rheumatology Associates of Long Island

I would use entecavir for Hep B reactivation prophylaxis in this case - based on recommendations from AGA 2025 guidelines, which does classify b-cell depleting agents as higher risk for reactivation for both Hep B surface Ag-positive and Hep B surface Antigen neg/core positive patients. It should be...

What is your approach to a situation where DILI is suspected secondary to an important medication (e.g., anticoagulation, antibiotics, etc.), but the diagnosis is uncertain and the liver injury is relatively mild?

4
2 Answers

Mednet MemberInvited Expert
Hepatology · Northwestern Memorial Hospital

If the drug suspected to induce liver injury causes symptoms and ALT is >3 times the upper limit of normal (ULN), I would stop the drug and find an alternative. Even if no symptoms are present, I would stop if ALT is >5 times ULN. Any level increase of ALT below the above parameters would still requ...

Following long-term efficacy and safety data from the beti-cel trials, how do you approach gene therapy for eligible patients with transfusion-dependent β-thalassemia?

2 Answers

Mednet MemberInvited Expert
Hematology · Boston University School of Medicine

The results with beti-cel are excellent. So are the results with exa-cel. These two gene therapies use different approaches to modifying hemoglobin production in erythroid stem cells. Beti-cel adds a modified hemoglobin that resembles fetal hemoglobin using viral-mediated transduction, whereas exa-c...

How do you decide when to pursue malignancy workup for patients with cryptogenic stroke?

1
4 Answers

Mednet Member
Neurology · Advocate Medical Group Neurology

Agree with above. I would also pursue malignancy work-up in this scenario as well: currently on anticoagulation (whether for afib or another medical reason) and has an ischemic stroke on top of that.